Chart-Typ:
Zeitraum:
| Metavista3D Inc.: Metavista3D Announces Application for Management Cease Trade Order | VANCOUVER, BC / ACCESS Newswire / April 15, 2025 / Metavista3D Inc. (TSXV:DDD)(FSE:E3T) ("Metavista3D" or the "Company") announces that as a result of delays in the completion of its audit, the Company... ► Artikel lesen |
| EQS-News: Metavista3D, Inc.: Metavista3D ernennt Neil E. Hide zum Chief Operating Officer | EQS-News: Metavista3D, Inc.
/ Schlagwort(e): Miscellaneous
Metavista3D ernennt Neil E. Hide zum Chief Operating Officer
07.04.2025 / 07:00 CET/CEST
Für den Inhalt der... ► Artikel lesen |
| Metavista3D, Inc.: Metavista3D Appoints Neil E. Hide as Chief Operating Officer | Vancouver, British Columbia--(Newsfile Corp. - April 7, 2025) - Metavista3D Inc. (TSXV: DDD) (FSE: E3T) ("Metavista3D" or the "Company"), announces the appointment of Neil E. Hide as Chief Operating... ► Artikel lesen |
| Pre-market Movers: Nukkleus, Versus Systems, Zeo Energy, Old Market Capital, FOXO Technologies | LOWELL (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.40 A.M. ET).In the Green Nukkleus Inc. (NUKK) is up over 60% at $32.84.
Versus... ► Artikel lesen |
| Versus Systems Inc.: Versus Systems Expands into Brazil, One of the World's Largest Gaming Markets | MIAMI, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Versus Systems, Inc. (NASDAQ: VS) (the "Company") announces its expansion into Brazil, one of the largest global gaming markets with more than 100 million... ► Artikel lesen |
| Akero Therapeutics Inc.: Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | -- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed... ► Artikel lesen |
| Akero Therapeutics Inc.: Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH-by Both Completer and ITT Analyses-at Week 96 in Phase ... | Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated =1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over... ► Artikel lesen |
| Akero Therapeutics Inc.: Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | - First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH - - Phase 3 SYNCHRONY Real-World and Histology... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAISON SOLUTIONS INC finden Sie auf Wallstreet Online.
